Rationale The ventral tegmental area (VTA) mediates the local stimulating effects of ethanol (EtOH) in a regiondependent manner, with EtOH administration in the posterior but not anterior VTA stimulating the mesolimbic system. The serotonin-3 (5-HT 3 ) receptor has been involved in the effects of EtOH on the mesolimbic system. Objectives The current study tested the hypothesis that EtOH would stimulate mesopallidal and mesocortical dopamine neurons in the posterior but not anterior VTA and that the stimulating effects of EtOH in the VTA would involve activation of local 5-HT 3 receptors. Methods Wistar female rats were surgically implanted with two cannulae, one in one sub-region of the VTA for microinjection and the other in the ventral pallidum (VP) or medial prefrontal cortex (mPFC) for microdialysis. Artificial cerebrospinal fluid or EtOH (200 mg%; 44 mM) was microinjected in the anterior or posterior VTA, and extracellular dopamine was measured in the VP or mPFC with microdialysis-HPLC. Results EtOH injections in the posterior but not anterior VTA significantly increased extracellular dopamine levels in the VP and mPFC. Co-injections of the 5-HT 3 receptor antagonist 930 with EtOH in the posterior VTA significantly reduced the effects of EtOH on extracellular dopamine levels in the VP and mPFC. Conclusions The results indicate that posterior VTA dopamine neurons projecting to the VP and mPFC are stimulated by local administration of EtOH and that the local stimulating effects of EtOH are mediated, at least in part, by 5-HT 3 receptors.
Introduction
Dopamine (DA) neurons in the ventral tegmental area (VTA) and their projections to the forebrain cortico-limbic regions have been implicated in mediating the effects of drugs of abuse, including ethanol (EtOH; Koob and Volkow 2010; McBride et al. 1999) . Systemic administration of EtOH activates the mesolimbic DA system and increases extracellular DA levels in the nucleus accumbens (NAc; Imperato and Di Chiara 1986; Weiss et al. 1993 ). This effect of EtOH is thought to be largely due to EtOH actions in the VTA. This notion is supported by several lines of studies. Electrophysiological studies showed that both systemic and local administration of EtOH-stimulated VTA DA neurons (Brodie et al. 1990 (Brodie et al. , 1999 Foddai et al. 2004; Gessa et al. 1985) . In addition, intra-VTA microinjections of EtOH increased DA release in the NAc (Ding et al. 2009b) . Furthermore, the stimulating effects of EtOH were demonstrated only in the posterior VTA (pVTA), but not the anterior VTA (aVTA), suggesting a regional difference in the action of EtOH (Ding et al. 2009b ). This finding is consistent with behavioral studies that EtOH was reinforcing in the pVTA but not aVTA (Rodd-Henricks et al. 2000; Rodd et al. 2004) . Overall, the current evidence suggests that EtOH can stimulate pVTA DA neurons projecting to the NAc.
VTA DA neurons also project to the ventral pallidum (VP) and medial prefrontal cortex (mPFC; Oades and Halliday 1987) . These two regions, along with the VTA and NAc, form a complex circuit involved in mediating the rewarding and reinforcing effects of EtOH (Koob and Volkow 2010) . However, the stimulating effects of EtOH on the mesopallidal and mesocortical systems have not been fully explored. Previous studies showed that systemic administration of EtOH increased extracellular DA levels in the VP . No study thus far has examined whether this effect is due to the activation of mesopallidal DA neurons in the VTA and/or is due to EtOH effects on DA terminals in the VP. On the other hand, the effects of systemic EtOH on the mesocortical DA system are not so evident. Several studies indicated that intraperitoneal (IP) injection of EtOH did not alter extracellular DA levels in the mPFC (Engleman et al. 2006; Hegarty and Vogel 1993) . However, a number of studies have linked the mPFC DA transmission in mediating the effects of ethanol. For example, pharmacological manipulations of DA receptor function in the mPFC or 6-hydroxydopamine lesion of the mPFC altered voluntary ethanol consumption (Nielsen et al. 1999) or operant responding for EtOH in rats (Hodge et al. 1996; Samson and Chappell 2003) . In addition, the alcohol-preferring P rat has lower basal extracellular DA concentrations in the mPFC compared with the Wistar rat, suggesting lower DA transmission in the mPFC may be associated with alcohol preference and drinking (Engleman et al. 2006) . Given these results, further studies are warranted to explore the neurochemical effects of EtOH on the mesocortical DA system.
In the present study, effects of EtOH on extracellular DA levels in the mPFC and VP were examined with local application of EtOH in the VTA. Given the stimulating effects of EtOH on mesolimbic DA neurons, we hypothesize that EtOH would activate VTA DA neurons projecting to the VP and mPFC and the effects would be evident in the pVTA but not aVTA.
The reinforcing and stimulating effects of EtOH appear to involve the 5-HT 3 receptor. Systemic administration of 5-HT 3 receptor antagonists suppressed voluntary EtOH consumption in rats under 24-h free-choice conditions (Knapp and Pohorecky 1992; McKinzie et al. 1998 ). Coinfusion of 5-HT 3 receptor antagonists with EtOH attenuated EtOH self-infusions in the pVTA . Furthermore, both systemic and local application of the 5-HT 3 receptor antagonist ICS-205,930 attenuated the systemic EtOH-induced increase of extracellular DA levels within the mesolimbic system (Campbell et al. 1996; Campbell and McBride 1995; Wozniak et al. 1990 ). However, no study has examined the involvement of 5-HT 3 receptors in the local stimulating effects of EtOH on DA neurons in the VTA. Therefore, we hypothesize that the local stimulating effects of EtOH on DA neurons in the pVTA would involve the activation of 5-HT 3 receptors.
Methods and materials
Subjects Adult female Wistar rats (250 to 320 g, Harlan, Indianapolis IN, USA) were housed in a temperature-and humidity-controlled room maintained on a reversed 12-h light-dark cycle (light off at 9:00 AM). Rats were housed in pairs upon arrival and individually after the surgery. Food and water were freely available except in the testing chambers. Female rats were used because they maintain their head size better than male rats for more accurate stereotaxic placements (Ding et al. 2009b; Ikemoto et al. 1997a; Rodd-Henricks et al. 2000) . Although the estrous cycle was not monitored, counterbalanced experiments were conducted on different days so that any effect of a given phase of the estrous cycle was distributed across experiments. Protocols were approved by the Institutional Animal Care and Use Committee of Indiana University School of Medicine and were in accordance with principles in the Guide for the Care and Use of Laboratory Animals (National Research 1996) . Surgery and probe insertion procedures Guide cannulae were implanted in the ipsilateral side of the brain as previously described (Ding et al. 2009b ). The target regions were: aVTA (AP, 4.8 mm; ML+2.1 mm; DV, 9.0 mm); pVTA (AP, 5.6 mm; ML+2.1 mm; DV, 9.0 mm); VP (AP+ 0.1 mm; ML+2.3 mm; DV, 9.0 mm); and mPFC (AP+ 3.0 mm; ML+0.7 mm; DV, 5.0 mm; Paxinos and Watson 1998) . Cannulae were inserted into the VTA with a 10 o angle to vertical and into the VP or mPFC with no angle. Probes (inner diameter, 200 μm; molecular weight cut-off, 13,000; Spectrum Laboratories, Inc, Rancho Dominguez, CA) were inserted into the VP (1.5-mm active membrane) or mPFC (2.0-mm active membrane) as described previously (Ding et al. 2009b ).
Chemical agents
Microinjection procedure EtOH and ICS-205,930 were dissolved in artificial cerebrospinal fluid (aCSF) to the desired concentrations prior to use. Microinjections were conducted with an electrolytic micro-infusion transducer (EMIT) system, following the procedure described previously (Ding et al. 2009b) . Briefly, the EMIT system was calibrated to inject a 100-nl solution in 5 s; a 15-s timeout period followed each 5-s injection. The injection-timeout cycle was repeated 30 times over a 10-min period. After the injection, the injector remained in place for 1 min before being removed.
Microdialysis procedure Microdialysis was conducted following procedures described previously (Ding et al. 2009b) . Briefly, microdialysis started 16-18 h after the probe insertion. Rats were placed into microdialysis chambers and connected to a Harvard pump. Microdialysis started with a 90-min washout period with the perfusion of aCSF through probes at a rate of 1.0 μl/min. After the washout period, four to five baseline samples were collected, which was followed by microinjections of either vehicle or the drug for 10 min in the sub-region of the VTA. Five samples were collected thereafter. Samples were collected at 10-min intervals.
Sample analysis DA was analyzed with a reversed-phase high-performance liquid chromatography coupled with electrochemical detection, as described previously (Thielen et al. 2004) . Briefly, 5-ul samples were delivered onto an analytical column (BDS Hypersil C18, 3 μm, 100 mm×1 mm, Thermo) with a mobile phase containing 77.0 mM NaC 2 H 3 O 2 , 0.5 mM EDTA, 3.4 mM SOS, 9.9 mM NaCl, and 6.0% acetonitrile, pH 4.0. DA was detected with a glassy-carbon electrode and an amperometric detector with the oxidation potential set at +450 mV and sensitivity set at 1 nA/V. The signal then was analyzed with a ChromPerfect data station. The detection limit for DA was approximately100 pmol/l with a signal-to-noise ratio of 3:1.
The effects of EtOH in different sub-regions of the VTA on extracellular DA levels in the VP Rats were randomly assigned to the following groups (n=5-8/group). Two groups received either aCSF or EtOH (200 mg%; 44 mM) in the aVTA; and the other two groups received either aCSF or 200 mg% EtOH in the pVTA. Extracellular DA was sampled in the VP. For female Wistar rats, the 200 mg% EtOH (44 mM) appeared to be an optimal concentration to be self-infused into the pVTA (Rodd-Henricks et al. 2000) and to increase DA release in the NAc after being injected into the pVTA (Ding et al. 2009b) .
The second experiment examined the involvement of the 5-HT 3 receptor in the effects of EtOH in the pVTA where local administration of EtOH increased extracellular DA levels in the VP. Two groups of rats received co-infusion of the 5-HT 3 receptor antagonist ICS-205,930 (100 or 200 μM, n=5-8 per dose) and 200 mg% EtOH in the pVTA during the microdialysis. ICS-205,930 (100 μM) has been shown to attenuate self-infusion of EtOH into the pVTA . A third group received microinjections of the antagonist alone (200 μM, n=5) in the pVTA. To reduce the number of rats, groups receiving either EtOH (200 mg%) or aCSF alone in the pVTA were not repeated in this experiment because the first experiment outlined above already contained these groups. However, results from the first experiment were adopted for statistical analysis in this experiment.
The effects of EtOH in different sub-regions of the VTA on extracellular DA levels in the mPFC Rats were randomly assigned to the following groups (n=5-8/group). Two groups received microinjections of either aCSF or 200 mg % EtOH in the aVTA; and the other two groups received microinjections of either aCSF or 200 mg% EtOH in the pVTA. Extracellular DA levels in the mPFC were measured.
In the pVTA, where local administration of EtOH increased extracellular DA levels in the mPFC, the effects of co-infusion of the 5-HT 3 receptor antagonist ICS-205,930 with 200 mg% EtOH were examined, following the same procedure described above in experiment 2 in the study performed above.
Histology At the end of experiments, rats were euthanized, and bromophenol blue (1%) was delivered into the target regions. Brains were removed, and sections (40 μm) were prepared and stained, as described previously (Ding et al. 2009b ). The placement of injection sites and probes were determined in accordance with the rat brain atlas of Paxinos and Watson (1998) .
Statistical analysis DA levels were expressed as percent of baseline averaged from the last three baseline samples prior to the microinjection. Analyses of variance (ANOVA) with repeated measures were conducted to analyze the time-course data. Area under the curve (AUC) coupled with one-way ANOVA were used to analyze data from the ICS-205,930 coinfusion experiments. The AUC values were derived from time-course data of percentage DA levels. The calculation included all time points and used 100% as baseline. Significant difference was set at p<0.05. Post hoc Tukey's b tests were performed following significant major effects. Figure 1 shows placements of probes in the mPFC and VP. In the mPFC, probes were mainly in the prelimbic and infralimbic areas of the mPFC. Some probes also covered a small portion of the anterior cingulate. In the VP, probes were mainly in the VP area underneath the anterior commissure. Some probes also covered a small portion of the lateral globus pallidus to the dorsal side and a small portion of the nucleus of horizontal limb of the diagonal band (HDB) or the magnocellular preoptic nucleus to the ventral side. To be included in the analysis, rats had to have at least 75% of the probe in the VP or mPFC. Figure 2 shows the placement of micro-injection sites within the aVTA and pVTA. Previous studies indicated that the aVTA ranges from coronal section 4.8 to 5.2 mm posterior to bregma, and the pVTA ranges from coronal section 5.3 to 6.3 mm posterior to bregma ( Fig. 2 ; Ding et al. 2009b; Rodd-Henricks et al. 2000) . Approximately 80% of the rats fulfilled these criteria. Rats with injection sites outside of the VTA were not included in analysis.
Results

Histology
Effects on extracellular DA levels in the VP Figure 3 shows time-course effects of microinjections of aCSF or EtOH (200 mg%; 44 mM) in different sub-regions of the VTA on extracellular DA levels in the VP. The average basal extracellular DA levels in each group were shown in Table 1 . Mixed repeated-measures ANOVA with 'time' as within factor and 'region' and 'treatment' as between factors revealed significant 'time × region × treatment' interaction (F 5, 11 =3.78, p=0.031). The significant interaction term allowed further analyses to be conducted in each individual sub-region of the VTA. In the pVTA, significant effects of 'time', 'treatment', and time × treatment interaction were found (all F values>3.87, all p values<0.05). Microinjections of 200 mg% EtOH in the pVTA significantly increased extracellular DA levels in the VP to approximately 160% of baseline levels, whereas microinjections of aCSF had no effect on extracellular DA levels (Fig. 3a) . In the aVTA, there was no significant effect of 'time', 'treatment' or 'time × treatment' interaction (all F values<0.41, all p values>0.5). Microinjections of neither 200 mg% EtOH nor aCSF in the aVTA significantly altered extracellular DA levels in the VP (Fig. 3b) . Furthermore, EtOH produced a significantly greater effect in the pVTA than aVTA (F 1, 8 =6.43, p=0.035) . Figure 4 shows the effects of co-injections of the 5HT 3 receptor antagonist ICS-205,930 (100 or 200 μM) with EtOH in the pVTA. The basal DA levels in each group were shown in Table 1 . AUC values were calculated from each group and were analyzed with one-way ANOVA (Fig. 4) . The analysis indicated a significant effect of treatment (F 4, 23 Effects on extracellular DA levels in the mPFC Figure 5 shows the time-course effects of microinjections of aCSF or 200 mg% EtOH into different sub-regions of the VTA on extracellular DA levels in the mPFC. Basal extracellular DA levels in each group were shown in Table 1 . Mixed repeated-measures ANOVA with 'time' as within factor and 'region' and 'treatment' as between factors revealed a significant 'time × region × treatment' interaction (F 7,16 =3.07, p=0.03). Further statistical analyses followed the same procedure as outlined above for data shown in Fig. 3 . Microinjections of 200 mg% EtOH into the pVTA significantly increased extracellular DA levels in the mPFC to approximately 150% of baseline levels (F 1, 12 =10.14, p< 0.05); microinjections of aCSF, on the other hand, had no effect (Fig. 5a ). In the aVTA, however, neither aCSF nor 200 mg% EtOH significantly altered mPFC DA levels (all F values<1.98, all p values>0.05, Fig. 5b) . Similarly, EtOH produced greater effects in the pVTA compared with the aVTA (F 1, 13 =14.98, p=0.002). Figure 6 shows the effects of co-injection of the 5HT 3 receptor antagonist ICS-205,930 (100 or 200 μM) on the actions of EtOH in the pVTA. The basal DA levels in each group were shown in Table 1 . AUC analysis indicated a significant effect of treatment (Fig. 6, F alone did not significantly alter extracellular DA levels in the mPFC.
Since ICS-205,930 also interacts with the GABA A receptor at high micro-molar ranges (Klein et al. 1994 ), a separate preliminary experiment was carried out to assess the involvement of GABA A receptors in the local reinforcing actions of EtOH on DA neurons within the pVTA. In a intracranial self-administration paradigm (Ding et al. 2009c; Rodd-Henricks et al. 2000) , Wistar rats readily responded for the self-infusion of 200 mg% EtOH alone into the pVTA and discriminated the active from the inactive lever (Fig. 7 , Rodd-Henricks et al. 2000 . Coadministration of 250 μM bicuculline, a GABA A receptor antagonist, with 200 mg% EtOH did not significantly alter responding on the EtOH lever (Fig. 7) , suggesting that activation of GABA A receptors are not involved in the local stimulating effects of EtOH within the pVTA.
Discussion
The current study demonstrated that local administration of EtOH into the pVTA but not aVTA increased DA release in both the VP and mPFC (Figs. 3 and 5) and that coinjections of the 5-HT 3 receptor antagonist ICS-205,030 attenuated the local stimulating effects of EtOH on pVTA DA neurons projecting to the VP and mPFC (Figs. 4 and  6 ). These results suggest that DA neurons in the pVTA, but not the aVTA, are stimulated by EtOH and the stimulating effects of EtOH are mediated, at least in part, by activation of local 5-HT 3 receptors.
Local application of 200 mg% EtOH in the pVTA significantly increased extracellular DA levels in the VP to approximately 160% of baseline (Fig. 3) , indicating EtOH stimulation of mesopallidal DA neurons in the pVTA. These findings suggest that local stimulation of pVTA mesopallidal DA neurons may underlie the neurochemical effects of systemically administered EtOH on the mesopallidal DA system . However, the results of the present study do not eliminate the possibility that systemic EtOH could also have an effect directly within the VP. The elevation of extracellular DA levels in the VP may be involved in some important functions, such as locomotor activation (Klitenick et al. 1992) . Two studies have also linked VP DA to EtOH selfadministration in alcohol-preferring P rats (Melendez et al. , 2005 . Intracranial self-administration experiments were conducted as previously described ). *p<0.05, significantly higher responses on the active than inactive lever, and significantly higher responses on the active lever compared with responses by the aCSF group. Responses on the active lever with 200 mg% EtOH alone were not significantly different than responses with 200 mg% EtOH plus 250 μM bicuculline Direct application of EtOH into the pVTA also stimulates mesocortical DA neurons, as indicated by elevated DA release in the mPFC (Fig. 5) . These findings are in contrast to previous reports that systemic administration of EtOH did not alter extracellular levels of DA in the mPFC (Engleman et al. 2006; Hegarty and Vogel 1993) . Reasons for this apparent disagreement between the IP injection and microinjection studies may be due to local administration of ethanol only acting on DA cell bodies within the VTA, whereas systemic administration of ethanol acts not only on the cell bodies in the VTA, but also in terminal areas within the mPFC. It is possible that systemically administered EtOH may produce certain inhibitory effects on DA terminals within the mPFC, which overrides the stimulatory effects of ethanol in the cell body area. In the mPFC, there appears to be tonic GABA-mediated inhibition of DA release (Santiago et al. 1993) . EtOH has been shown to increase both GABA A and GABA B receptor-mediated inhibition (Allan et al. 1987; Federici et al. 2009 ). Therefore, a tentative hypothesis can be proposed that EtOH in the mPFC could inhibit DA release locally by enhancing GABAergic inhibition, which could counteract the stimulating effects of EtOH in the VTA. Another possibility to explain why systemic EtOH did not alter mPFC DA levels may be due to EtOH activating inhibitory projections from other brain regions to the mPFC, which inhibits DA release within the mPFC. Further studies will be needed to test these possibilities.
The current study suggested that activation of local 5-HT 3 receptors may be involved in the stimulating effects of EtOH on DA neurons in the pVTA, as demonstrated by the findings that co-infusion of the 5-HT 3 receptor antagonist ICS-205,930 significantly attenuated EtOH-induced DA release in the VP and mPFC (Figs. 4 and 6 ).These findings are consistent with findings showing co-infusion of 5-HT 3 receptor antagonists inhibit the local reinforcing actions of EtOH in the pVTA , as well as findings demonstrating that local perfusion of ICS-205,930 attenuated systemic EtOH-induced DA increase in both the VTA and NAc (Campbell et al. 1996; Campbell and McBride 1995) .
Activation of 5-HT 3 receptors within the pVTA can increase DA neuronal activity and produce reinforcing effects. The 5-HT 3 receptor agonist, 1-(m-chlorophenyl)-biguanide (CPBG), can be self-administered into the pVTA (Rodd et al. 2007 ) and increase local extracellular DA levels (Campbell et al. 1996; Liu et al. 2006) . Furthermore, EtOH can increase the 5-HT 3 receptor-mediated current in vitro (Lovinger and White 1991; Machu and Harris 1994) and local application of CPBG can enhance the systemic EtOH-induced increase of extracellular DA levels in the VTA (Campbell et al. 1996) . Therefore, research with both 5-HT 3 agonists and antagonists discussed above suggests that EtOH can stimulate DA neurons in the pVTA via enhancing the activity of 5-HT 3 receptors and that the inhibition of 5-HT 3 receptors would attenuate the stimulating effects of EtOH.
Low to moderate densities of 5-HT 3 receptor binding sites were detected in the VTA with receptor autoradiography (Ge et al. 1997) . Although the cellular localization of 5-HT 3 receptors is not known, the VTA DA neuron is a strong candidate because of the demonstrated synaptic connectivity of 5-HT terminals on VTA DA neurons (Van Bockstaele et al. 1994 ). The 5-HT 3 receptors on DA neurons could be involved in the effects of EtOH, as activation of these 5-HT 3 receptors would directly stimulate DA neurons. However, 5-HT 3 receptors on GABA interneurons and/or GABA terminals may not be involved in the EtOH effect, as activation of these receptors would increase GABA release onto DA neurons.
At micro-molar concentrations, ICS-205,930 has been shown to inhibit the GABA A receptor-mediated inhibition (Klein et al. 1994 ). Therefore, it is possible that ICS-205,930 could be acting at GABA A receptors to produce its inhibitory effects on EtOH-stimulated DA release. GABA A receptors form different circuits in regulating DA neuron activity within different sub-regions of the VTA (Arnt and Scheel-Kruger 1979; Ding et al. 2009a; Ikemoto et al. 1997b Ikemoto et al. , 1998 , with little tonic GABA A receptor-mediated inhibition in the pVTA. A preliminary study (Fig. 7) was conducted to examine the effects of a GABA A antagonist on the reinforcing stimulating effects of EtOH on DA neurons in the pVTA. The results of this study indicated that bicuculline had no effect on the self-infusion of EtOH in the pVTA, suggesting that the reinforcing stimulating effects of EtOH within the pVTA are not mediated via activation of local GABA A receptors. These latter results support the idea that the effects of 930 observed in the present study may be occurring through inhibition of 5-HT 3 receptors. This conclusion is consistent with a previous study indicating that zacropride, another 5-HT 3 receptor antagonist without an interaction at the GABA A receptor (Smith et al. 1988) , was more potent than ICS-205,930 in inhibiting EtOH selfadministration in the pVTA, suggesting that inhibition of local 5-HT 3 receptors alone was sufficient to prevent the stimulating actions of EtOH within the pVTA.
In addition, ICS-205,930 functions as a partial agonist at the α7 nicotinic receptor (Macor et al. 2001 ). In the VTA, these receptors are located pre-synaptically on glutamatergic terminals (Jones and Wonnacott 2004) and are involved in the stimulation of DA neurons (Schilstrom et al. 1998 ). However, several lines of evidence suggest these receptors may not be involved in the effects of 930 observed in the present study (Figs. 4 and 6) . First, α7 nicotinic receptors may not mediate the stimulating effects of EtOH as demonstrated by findings that EtOH can inhibit the activity of the α7 nicotinic receptor (Narahashi et al. 1999) . Second, the findings that microinjection of 200 μM ICS-205,930 alone did not significantly alter extracellular DA levels in the VP and mPFC suggest that the action of ICS-205,930 on α7 nicotinic receptors did not produce general inhibition of DA neurons. Therefore, the effects of ICS-205,930 observed in the present study are not likely due to an action on local α7 nicotinic receptors.
The stimulating effects of EtOH within the VTA appear to be subregion-dependent. Local application of 200 mg% (44 mM) EtOH in the pVTA, but not aVTA, induced a comparable increase (50-60%) of extracellular DA levels in the NAC, VP and mPFC (Figs. 3 and 5) (Ding et al. 2009b) . These findings are consistent with behavioral studies demonstrating that EtOH is reinforcing in the pVTA but not aVTA (Rodd-Henricks et al. 2000) and suggest that activation of mesopallidal and mesocortical systems, in addition to the mesolimbic system, may contribute to the reinforcing properties of EtOH in the pVTA. Together, these studies suggest that the pVTA is more sensitive than the aVTA to the stimulating effects of EtOH. The mechanisms for this difference are unknown. One possibility may be related to possible differential projections to the target regions from the two VTA sub-regions. However, neuro-anatomical evidence does not support this idea because both the aVTA and pVTA appear to project to the VP and mPFC (Klitenick et al. 1992; Swanson 1982) . Another possibility may be differences in receptors and/or neuronal circuits between the two sub-regions, e.g., 5-HT 3 receptors. The pVTA appeared to be more sensitive to 5-HT 3 receptor activation than the aVTA (Liu et al. 2006; Rodd et al. 2007) , which may contribute to the differential effects of EtOH between the two sub-regions of the VTA. The differential functions of 5-HT 3 receptors may be due to differential expression of 5-HT 3 receptors between the aVTA and pVTA; however, further neuro-anatomical studies need to be conducted to test this hypothesis.
In addition to the 5-HT3 receptor, other mechanisms may also contribute to the differential effects of EtOH. Evidence has shown that EtOH can directly activate VTA DA neurons (Brodie et al. 1999) , which may be through the actions of EtOH on certain voltage-dependent ion channels (Brodie and Appel 1998; Okamoto et al. 2006 ) and/or α4β2 nicotinic receptors in VTA DA neurons (Narahashi et al. 1999) . On the other hand, EtOH could indirectly stimulate DA neurons via suppression of GABA interneurons through either increasing opioid receptor neurotransmission to GABA inter-neurons (Johnson and North 1992) and/or decreasing NMDA receptor functions on these neurons (Stobbs et al. 2004) . It is possible that some or all of these mechanisms may exist in the pVTA but not in the aVTA, thus contributing to the differential effects of EtOH between these two sub-regions. Further studies will be needed to address the mechanisms of differential effects of EtOH within the VTA.
In summary, the present study indicated that direct application of EtOH in the pVTA but not aVTA stimulates local mesopallidal and mesocortical DA neurons. These findings suggest that activation of these systems may be involved in mediating the local effects of EtOH. Furthermore, the stimulating effects of EtOH within the pVTA appeared to be mediated, at least in part, by activation of local 5-HT 3 receptors, as indicated by the reduction of EtOH effects by co-infusions of the 5-HT 3 receptor antagonist 930. 
